Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: the SOLAR Trial

Launched by DANA-FARBER CANCER INSTITUTE · May 7, 2021

Keywords

ClinConnect Summary

The SOLAR Trial is a clinical study designed to find out if starting a special type of radiation treatment called stereotactic body radiation therapy (SBRT) early can help patients with advanced adenoid cystic carcinoma (ACC). This type of cancer can spread to other parts of the body, known as metastasis. The researchers want to see if using SBRT earlier affects how the disease progresses, improves the quality of life for patients, and increases overall survival rates.

To join the trial, participants need to be adults aged 18 or older with confirmed ACC that has spread to one to five sites in the body. They should also have a primary tumor that is either controlled or can be treated with SBRT. Patients who have previously received certain treatments may still be eligible if their condition is stable. Throughout the trial, participants will receive the SBRT treatment and be closely monitored to assess its effects. It’s important for potential participants to discuss their medical history and any other treatments they are undergoing with their healthcare provider to ensure they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject must have histologically confirmed adenoid cystic carcinoma (ACC) of any primary site with distant metastases detected clinically or on imaging (biopsy of metastatic disease preferred, but not required)
• • Cohort 1
• • One to five detectable sites of metastatic disease at any organ or site (including bone and CNS involvement)
• • Maximum size of 3 cm for brain lesions.
• • Note: Measurable disease is not required
• • Note: Patients with isolated intracranial disease for whom SRS would be the preferred standard of care are not eligible.
• • Note: Patients may have additional sites of disease for which radiation is not feasible or indicated provided this disease is: 1) Less than 1 cm in maximum diameter on most recent imaging; or 2) Stable over the last 3 months as determined by the investigator
• • Cohort 2
• • At least 1 site of non-osseous disease
• • Cohort 1
• • All (up to 5) metastatic foci should be amenable to SBRT as per review by a radiation oncologist based on protocol specified dose / dose constraints (there is no prespecified minimum or maximum size)
• • Cohort 2
• • At least one metastatic focus amenable to local ablative treatment with any of the following: radiation therapy; radiofrequency, microwave, or cryoablation; bland or chemoembolization
• • Cohort 1
• • Primary tumor either controlled, or amenable for local treatment with SBRT
• • Defined as no evidence of progression at primary or local site of disease (if known) within 6 months prior to enrollment
• • Age 18 years or older
• • ECOG performance status of 0-2
• • Prior systemic therapy is allowed but no therapy (cytotoxic or molecularly targeted agents) 2 weeks prior to the first fraction of radiotherapy, and until after the last fraction of SBRT.
• • Cohort 1
• * For patients with metastases that have been previously treated (prior resection, radiotherapy, radiofrequency or cryoablation):
• • If the previously treated site is controlled based on imaging, the patient is eligible for this trial and does not need further treatment of the controlled site
• • If the previously treated site is not controlled based on imaging, the patient is eligible for this trial as long as the site is amenable to SBRT
• • Ability to understand and the willingness to sign a written informed consent document.
• • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of (chemo)radiation therapy.
• • "Women of childbearing potential (WOCBP)" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.
• • Men who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 1 month after treatment. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception. See Appendix B for further guidance on contraception.
• Exclusion Criteria:
• • Cohort 1
• • Subject who has received systemic therapy for treatment of ACC within 2 weeks of enrollment.
• • Evidence of need for urgent surgical intervention for metastatic CNS or spine disease.
• • Cohort 1
• • Alternative locally ablative therapies received (radiofrequency ablation, cryotherapy, or \[chemo\]embolization) for any metastatic foci planned for SBRT at the time of study enrollment that precludes administration of SBRT.
• • Bone metastasis in a femoral bone for which surgical stabilization is recommended.
• • Cohort 1
• • Active disease \>1 cm that is progressing and not amenable to SBRT.
• • Pregnant or lactating women.
• • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• • Has a known additional malignancy that is progressing or requires active treatment. Exceptions: include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, and low-risk prostate adenocarcinoma being managed with active surveillance. A history of another separate malignancy in remission without evidence of active disease in the last 2 years is permitted.